Incidence, Diagnosis and Prognosis of Cardiac Amyloidosis

다국어 초록 (Multilingual Abstract)

Background and Objectives: Cardiac involvement is frequent in systemic amyloidosis and is the most important determinant of the clinical outcome. The aims of this study were to assess the incidence and prognosis of cardiac amyloidosis and discuss the diagnostic issues related to cardiac amyloidosis.
Subjects and Methods: We retrospectively studied all patients diagnosed with systemic amyloidosis who presented to our institution from January 1999 to December 2011.
Results: Of the 129 patients with systemic amyloidosis, cardiac amyloidosis was diagnosed in 62 patients. At the 3 years’ follow-up of the patients with systemic amyloidosis, there was a statistically significant difference in mortality between patients with cardiac amyloidosis and the rest of the patients (58.1% vs. 37.3%, p=0.008). In the Cox proportional hazard model, old age {hazard ratio (HR) 18.336, p=0.006}, elevation of cardiac troponin I (cTNI) (HR 13.246, p=0.020), left ventricular (LV) systolic dysfunction (HR 5.137, p=0.041) and diastolic dysfunction (HR 64.595, p=0.022) were independently associated with survival in cardiac amyloidosis. In the diagnosis of monoclonal gammopathy, serum or urine protein electrophoresis was not sensitive enough to be used clinically compared to serum free light chain assay (35.8% vs. 96.4%).
Conclusion: In systemic amyloidosis, cardiac involvement was the most important determinant of the prognosis, and old age, elevation of cTNI, LV systolic dysfunction and diastolic dysfunction were independently associated with survival in cardiac amyloidosis.

참고문헌 (Reference)

1 Merlini G, "The systemic amyloidoses: clearer understandingof the molecular mechanisms offers hope for more effectivetherapies" 255 : 159-178, 2004

2 Falk RH, "The systemic amyloidoses: an overview" 45 : 107-137, 2000

3 Dubrey SW, "The clinical features of immunoglobulinlight-chain (AL) amyloidosis with heart involvement" 91 : 141-157, 1998

4 Dispenzieri A, "Survival in patients with primarysystemic amyloidosis and raised serum cardiac troponins" 361 : 1787-1789, 2003

5 Cueto-Garcia L, "Serial echocardiographic observationsin patients with primary systemic amyloidosis: an introductionto the concept of early (asymptomatic) amyloid infiltrationof the heart" 59 : 589-597, 1984

6 Klein AL, "Serial Doppler echocardiographicfollow-up of left ventricular diastolic function in cardiac amyloidosis" 16 : 1135-1141, 1990

7 Syed IS, "Role of cardiac magnetic resonanceimaging in the detection of cardiac amyloidosis" 3 : 155-164, 2010

8 Klein AL, "Prognostic significance of Dopplermeasures of diastolic function in cardiac amyloidosis. A Dopplerechocardiography study" 83 : 808-816, 1991

9 Kyle RA, "Primary systemic amyloidosis: multivariateanalysis for prognostic factors in 168 cases" 68 : 220-224, 1986

10 Lachmann HJ, "Outcome in systemic ALamyloidosis in relation to changes in concentration of circulating freeimmunoglobulin light chains following chemotherapy" 122 : 78-84, 2003

11 Rahman JE, "Noninvasive diagnosis ofbiopsy-proven cardiac amyloidosis" 43 : 410-415, 2004

12 Kristen AV, "Non-invasive predictors ofsurvival in cardiac amyloidosis" 9 : 617-624, 2007

13 Perugini E, "Non-invasive evaluation of themyocardial substrate of cardiac amyloidosis by gadolinium cardiacmagnetic resonance" 92 : 343-349, 2006

14 Palladini G, "New criteria for responseto treatment in immunoglobulin light chain amyloidosis based on freelight chain measurement and cardiac biomarkers: impact on survivaloutcomes" 30 : 4541-4549, 2012

15 Seldin DC, "Improvement in qualityof life of patients with AL amyloidosis treated with high-dose melphalanand autologous stem cell transplantation" 104 : 1888-1893, 2004

16 Skinner M, "High-dose melphalanand autologous stem-cell transplantation in patients with AL amyloidosis:an 8-year study" 140 : 85-93, 2004

17 Nishimura RA, "Evaluation of diastolic filling of left ventriclein health and disease: Doppler echocardiography is the clinician’s RosettaStone" 30 : 8-18, 1997

18 Dispenzieri A, "Eligibility for hematopoieticstem-cell transplantation for primary systemic amyloidosis is a favorableprognostic factor for survival" 19 : 3350-3356, 2001

19 Arbustini E, "Electronand immuno-electron microscopy of abdominal fat identifiesand characterizes amyloid fibrils in suspected cardiac amyloidosis" 9 : 108-114, 2002

20 Murtagh B, "Electrocardiographicfindings in primary systemic amyloidosis and biopsy-proven cardiac involvement" 95 : 535-537, 2005

21 Klein AL, "Doppler characterization of leftventricular diastolic function in cardiac amyloidosis" 13 : 1017-1026, 1989

22 Morris KL, "Diagnostic and prognostic utility ofthe serum free light chain assay in patients with AL amyloidosis" 37 : 456-463, 2007

23 Duston MA, "Diagnosis of amyloidosisby abdominal fat aspiration. Analysis of four years’ experience" 82 : 412-414, 1987

24 Gertz MA, "Definition of organ involvementand treatment response in immunoglobulin light chain amyloidosis(AL): a consensus opinion from the 10th International Symposium onAmyloid and Amyloidosis, Tours, France, 18-22 April 2004" 79 : 319-328, 2005

25 Palladini G, "Circulating amyloidogenic freelight chains and serum N-terminal natriuretic peptide type B decreasesimultaneously in association with improvement of survival in AL" 107 : 3854-3858, 2006

26 Vogelsberg H, "Cardiovascular magneticresonance in clinically suspected cardiac amyloidosis: noninvasiveimaging compared to endomyocardial biopsy" 51 : 1022-1030, 2008

27 Kyle RA, "Amyloidosis (AL). Clinical and laboratory featuresin 229 cases" 58 : 665-683, 1983

28 Westermark P, "Amyloid fibril proteinnomenclature -- 2002" 9 : 197-200, 2002

29 Hamer JP, "Amyloid cardiomyopathyin systemic non-hereditary amyloidosis. Clinical, echocardiographicand electrocardiographic findings in 30 patients with AA and 24 patientswith AL amyloidosis" 13 : 623-627, 1992

30 Carroll JD, "Amyloid cardiomyopathy: characterizationby a distinctive voltage/mass relation" 49 : 9-13, 1982